Deep venous thrombosis prophylaxis in patients with heart disease

Current Cardiology Reports

Volumn 3, Issue 1, 2001, Pages 56-62

  Shively, Bruce K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; HEPARIN;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; HEART INFARCTION; HUMAN; INTENSIVE CARE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

ANGINA, UNSTABLE; ANTICOAGULANTS; ENOXAPARIN; HEART FAILURE, CONGESTIVE; HEPARIN; HUMANS; INTENSIVE CARE; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0035234052     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0011-3     Document Type: Article

References (31)

1. Clagett GP, Anderson FA, Geerts W, et al.: Prevention of venous thromboembolism. Chest 1998, 114:531S-560S.
2. Samama MM, Cohen AT, Darmon J-Y, et al.: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill patients. N Engl J Med 1999, 341:793-800.
3. Hirsh J, Hull RD, Raskob GA: Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol 1986, 8:104B-113B.
4. Alpert JS, Dalen JE: Epidemiology and natural history of venous thromboembolism. Progr Cardiovasc Dis 1994, 36:417-422.
5. O'Connell JB, Bristow MJ: Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994, 13:S107-S112.
6. Donaldson MC: Chronic Venous Disorders. In In Vascular Medicine. Edited by Loscalzo J, Creaker MA, Dzau VJ. Boston: Little, Brown and Company, 1992: 1085-1098.
7. Strandness Jr. DE, Langlois Y, Cramer M: Long-term sequelae of acute venous thrombosis. J Am Med Assoc 1983, 250:1289-1292.
8. Agnelli G, Sonaglia F: Prevention of venous thromboembolism. Thromb Res 1997, 97:V49-V62.
9. Goldhaber SZ, Morpurgo M: Diagnosis, treatment, and prevention of pulmonary embolism. J Am Med Assoc 1992, 268:1727-1733.
10. Hull RD, Pineo GF: Prophylaxis of deep venous thrombosis and pulmonary embolism: current recommendations. Cur Concepts of Thromb 1998, 82:477-493.
11. Keane MG, Ingenito EP, Goldhaber SZ: Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. Chest 1994, 106:13-14.
12. Wisehart JH, Chapman CB: Dicumarol therapy in congestive heart failure. New Engl J Med 1948, 239:701-704.
13. Anderson GM, Hull E: The use of dicumarol as an adjunct to the treatment of congestive heart failure. S Med J 1948, 41:365-371.
14. Harvey WP, Finch CA: Dicumarol: Prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med 1950, 242:208-211.
15. Gallus AS, Hirsh J, Tuttle RJ: Small subcutaneous dose of heparin in prevention of venous thrombosis. N Engl J Med 1973, 288:545-551.
16. Gardlund B: Randomized, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996, 347:1357-1361.
17. Haas S: Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients. Sem Thromb Hemost 1999, 25:101-105.
18. Cade JF: High risk of the critically ill for venous thromboembolism. Crit Care Med 1982, 10:448-450.
19. Ryan TJ, Anderson JL, Antman, EM et al.: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. Circulation 1996, 94:2341-2350.
20. Dahan R, Houlbert D, Caulen C, et al.: Prevention of deep vein thrombosis in elderly medical in-patients by low molecular weight heparin: A randomized double-blind trial. Haemostasis 1986, 16:159-164.
21. Halkin H, Goldberg J, Modan M, et al.: Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982, 96:561-565.
22. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zuibate S, et al.: Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1998, 11:505-513.
23. Belch JJ, Lowe DO, Ward AG, et al.: Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981, 26:115-117.
24. Goldhaber SZ: Venous thromboembolism prophylaxis in medical patients. Thromb Haemost 1999, 82:889-901.
25. Hirsh DR, Ingenito EP, Goldhaber SZ: Prevalence of deep venous thrombosis among patients in medical intensive care. J Am Med Assoc 1995, 274:335-337.
26. Lederle FA: Heparin prophylaxis for medical patients? Ann of Intern Med 1998, 128:768-770.
27. Anderson FA, Wheeler HB, Goldberg RJ, et al.: The prevalence of risk for venous thromboembolism smong hospital patients. Arch Intern Med 1992, 152:1660-1664.
28. Harenberg J, Roebruck P, Heene DL: Subcutaneous lowmolecular- weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis 1996, 26:127-139.
29. Harenberg J, Kallenbach B, Martin U, et al.: Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990, 59:639-650.
30. Bergman JF, Neuhart E: A multicenter randomized doubleblind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996, 76:529-534.
31. Al-Khadra AS, Salem DN, Rand WM et al.: Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998, 31:749-753.